



Description générale

Hydroxycarbamide (also known as hydroxyurea) is an antineoplastic antimetabolite used in treatment protocols for chronic myeloproliferative disorders, and in the management of sickle cell disease.

INN	Hydroxycarbamide
Codes ATC	L01XX05
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2009 (TRS 958) pour Chronic myeloid leukaemia, not elsewhere classified Ajouté en 2009 (TRS 958) pour Squamous cell carcinoma of oropharynx Ajouté en 2011 (TRS 965) pour Other specified sickle cell disorders or other haemoglobinopathies Retiré en 2015 (TRS 994) pour Squamous cell carcinoma of oropharynx
Wikipédia	Hydroxycarbamide (hydroxyurea) ↗
DrugBank	Hydroxycarbamide (Hydroxyurea) ↗

Recommandations

Section Cytotoxic medicines

Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Indications

Chronic myeloid leukaemia, not elsewhere classified

Squamous cell carcinoma of oropharynx

Section Other medicines for haemoglobinopathies

Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies

